Sign In
Buy SUPN
$44.04
-0.0350 (-0.0794%)
At Close: Jun 03, 2026
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
07:51pm, Tuesday, 27'th Feb 2024
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.43 per share a year ago.
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:21am, Monday, 26'th Feb 2024
Besides Wall Street's top -and-bottom-line estimates for Supernus (SUPN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the q
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
11:06am, Tuesday, 20'th Feb 2024
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ROCKVILLE, Md., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
07:43pm, Thursday, 14'th Dec 2023
Mental health has been one of the hot topics in the medical industry over the past few years. Widespread awareness was brought to the public eye during the COVID-19 pandemic as people in prolonged loc
Supernus Pharmaceuticals: Derisked CNS Drug Portfolio Offers Attractive Buying Opportunity
02:22pm, Friday, 10'th Nov 2023
Supernus Pharmaceuticals has experienced revenue growth every year since its IPO in 2021, reaching $667m in 2022. The company has expanded its product portfolio through acquisitions, including the pur
Supernus (SUPN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
09:02pm, Wednesday, 08'th Nov 2023
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street est
Supernus Pharmaceuticals (SUPN) Reports Q3 Loss, Tops Revenue Estimates
08:17pm, Wednesday, 08'th Nov 2023
Supernus Pharmaceuticals (SUPN) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of $0.13. This compares to earnings of $0.03 per share a year ago.
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2023 Earnings Call Transcript
07:38pm, Wednesday, 08'th Nov 2023
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Peter Vozzo – Investor Relations Jack Khattar – Chief Executive Offi
Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:18am, Wednesday, 01'st Nov 2023
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
04:15pm, Wednesday, 25'th Oct 2023
ROCKVILLE, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
04:15pm, Wednesday, 27'th Sep 2023
ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics
09:56pm, Tuesday, 08'th Aug 2023
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare t
Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates
09:11pm, Tuesday, 08'th Aug 2023
Supernus Pharmaceuticals (SUPN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.23. This compares to earnings of $0.14 per share a year ago.
Radcliffe Capital Management, L.P. Acquires Stake in Portage Fintech Acquisition Corp
04:37pm, Thursday, 27'th Jul 2023
Radcliffe Capital Management, L.P. (Trades, Portfolio), a prominent investment firm, recently made a significant acquisition in the stock market.
